Pharnext raises $8.7 million after share issuance
Pharnext has completed fundraising of approximately $8.7 million which demonstrated the strong and continued support of the company’s historical shareholders. Following the completion of the capital increase, Daniel Cohen, Chief Executive Officer of the company, and Peter Collum, Chief Financial Officer of the company, will hold respectively 3.77% and 0.14% of the share capital.
The biopharmaceutical company Pharnext is carrying out a capital increase of approximately $8.7 million (€7.7 million) through the issue of 1,799,061 new ordinary shares to each of which a share subscription warrant (ABSA) is attached. This capital increase was subscribed mainly by existing shareholders, as well as by new institutional investors in the U.S. and members of Pharnext’s management, including the Chief Executive Officer and the Chief Financial Officer.
The proceeds from the capital increase will provide the company with the additional resources necessary to fund its activities over the next 12 months, including the finalization of the Phase 3 study protocol and other regulatory requirements for the development of PXT3003 in the treatment of Charcot-Marie-Tooth disease type 1A with the U.S. Food and Drug Administration and the European Medicines Agency.
The Born2Invest mobile app is covering the biotech industry news, business headlines, information on genetic engineering and biotechnology. Get the latest industry news here!
The issue price of an ABSA amounts to $4.85
The ABSAs were placed, with the cancellation of the shareholders’ preferential subscription right (DPS), by means of a private placement with qualified investors and a capital increase for the benefit of investors.
The issue price of an ABSA amounts to $4.85 (€4.28), including the issue premium, reflecting a 12.30% facial discount compared to the weighted average share price over the last 3 trading sessions. The issue price of an ABSA, including the theoretical value of a warrant (BSA), reflects a total discount of 29.92% compared to the 3-day VWAP.
Terms of the warrants
A BSA is attached to each new share. Four BSAs give the right to subscribe to 3 new ordinary shares of the company, at a price of $6.30 (€5.56) per share. The warrants may be exercised at any time during a period of 42 months from their issue. In the event that all the BSAs are exercised, a total number of 1,349,298 new additional ordinary shares of the company would be issued, representing a total amount of approximately $8.5 million (€7.5 million).
The theoretical value of each BSA, assuming volatility of 45% and based on the closing price on March 4th, 2020, amounts to $0.97 (€0.86). The warrants will be immediately detached from the New Shares as soon as they are issued and will not be listed.
Following the issue of the ABSAs, the company’s share capital will amount to $192,710 (€170,303), i.e. 17,030,328 ordinary shares, each with a par value of $0.01 (€0.01), representing approximately 111.81% of the company’s existing share capital.
CB LUX Sàrl, holding respectively 16.85% and 23.36% of the share capital of Pharnext
Lohas Sàrl, a company controlled by a member of the board of directors of the company in the person of Pierre Bastid, and CB LUX Sàrl, holding respectively 16.85% and 23.36% of the share capital of Pharnext prior to the completion of the fundraising, will hold respectively 19.18% and 24.32% of the share capital of the company.
Daniel Cohen, Chief Executive Officer of the company, and Peter Collum, Chief Financial Officer of the company, subscribe to the capital increase. Following the completion of the capital increase, they will hold respectively 3.77% and 0.14% of the share capital.
The admission of the New Shares to trading on the Euronext Growth market in Paris is scheduled to take place at the time of settlement and delivery, which is expected to occur on or about March 11th. They will be listed on the same trading line as the company’s existing ordinary shares.
(Featured image by Louis Reed via Unsplash)
DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.
This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.
First published in boursier.com, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.
Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.
Consolidation of the Fintech Sector Reinforces Mastercard’s Commitment to the Sector
Mauricio Schwartzmann, CEO of Mastercard Mexico, stressed that the firm's involvement with financial technology is long-term and goes hand in...
Canal de Isabel II Accelerates Towards Energy Self-Consumption
Canal de Isabel II will switch from the then state-of-the-art Pelton turbines of 1913 to producing green hydrogen from reclaimed...
Dogecoin: Doge Whales Return Due to Bullish Metrics
In the short term, Dogecoin is encountering its first major resistance at $0.075, although a larger obstacle lies at $0.08....
Exit for Kippy, which Had Closed Two Equity Crowdfunding Rounds
Kippy recently participated in the third batch of the A-Road acceleration and fundraising program which, through ongoing training and mentorship...
Laminar Pharma Opens a €5 Million Round through Capital Cell
Looking ahead to 2024, the group plans to reach break-even, when the European Medicines Agency approves its drug against glioblastoma,...
Business1 week ago
Gold and its Open Interest: Should You Invest in Gold?
Biotech4 hours ago
Laminar Pharma Opens a €5 Million Round through Capital Cell
Crowdfunding1 week ago
The FastucUP Campaign, Created to Encourage Sicilian Agribusiness Exports Started
Crypto2 weeks ago
Adomos Launches the First Global Platform Dedicated to Real Estate NFTs